Basic Information
| LncRNA/CircRNA Name | PCAT6 |
| Synonyms | NA |
| Region | GRCh38_1:202810954-202812156 |
| Ensemble | ENSG00000228288 |
| Refseq | NR_046325 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | gastric cancer |
| ICD-0-3 | C16 |
| Methods | qPCR, Luciferase reporter assay, Western blot |
| Sample | gastric cancer tissues, cell lines (BGC-823, SGC-7901, HGC-27, MKN45, GES-1) |
| Expression Pattern | up-regulated |
| Function Description | PCAT6 was overexpressed in gastric cancer tissues than those of paracancerous tissues. PCAT6 expression was negatively correlated to prognosis, tumor size, TNM (tumor node metastasis) stage and metastasis of gastric cancer. For in vitro experiments, overexpression of PCAT6 increased proliferation, migration, and invasion, whereas decreased apoptosis of gastric cancer cells. MicroRNA-30 was predicted as the target gene of TCAT6. EMT-related genes were also found to be upregulated except for E-cadherin (Figure 2F). The above data elucidated that overexpressed PCAT6 promotes GC development. |
| Pubmed ID | 30178843 |
| Year | 2018 |
| Title | PCAT6 participates in the development of gastric cancer through endogenously competition with microRNA-30. |
External Links
| Links for PCAT6 | GenBank HGNC NONCODE |
| Links for gastric cancer | OMIM COSMIC |